Ariprex™ is an atypical antipsychotic and it has been proposed that the efficacy of Ariprex™ is
mediated through a combination of partial agonist activity at Dopamine D2 and Serotonin 5-HT1A
receptors and antagonist activity at Serotonin 5-HT2A receptors. This is associated with improvement
of schizophrenia, bipolar disorder, major depressive disorder, irritability associated with autistic
disorder, and agitation associated with schizophrenia or bipolar disorder.
Schizophrenia, bipolar disorder, adjunctive treatment of major depressive disorder, irritability
associated with autistic disorder, agitation associated with schizophrenia or bipolar mania.
Dosage & administration
• Oral formulations: Administer once daily without regard to meals.
• IM injection: Wait at least 2 hours between doses. Maximum daily dose 30 mg.
Vomiting, nausea, akathisia, extrapyramidal disorder, somnolence, sedation, dizziness, insomnia,
tremor, restlessness, fatigue, blurred vision, salivary hypersecretion, constipation, pyrexia, drooling,
Special warnings and precautions for use
Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse
events (eg, stroke, transient ischemic attack, including fatalities).
Suicidality & antidepressants: Increased risk of suicidality in children, adolescents, young and adults
with major depressive disorder.
Tardive dyskinesia: Discontinue if clinically appropriate.
Metabolic changes: Atypical antipsychotic drugs have been associated with metabolic changes that
include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain.
Orthostatic hypotension: Use with caution in patients with known cardiovascular or
Seizures/Convulsions: Use cautiously in patients with a history of seizures.
Use caution when operating machinery.
Known hypersensitivity to Aripiprazole.
Caution should be exercised when Aripiprazole is taken in combination with other centrally acting
drugs and alcohol. Carbamazepine could cause an increase in Aripiprazole clearance and lower blood
levels. Ketoconazole, quinidine, fluoxetine or paroxetine can inhibit Aripiprazole elimination and
cause increased blood levels.
Use in pregnancy and lactation
Pregnancy: Pregnancy category C. It should be avoided during pregnancy.
Lactation: It is recommended that women receiving Aripiprazole should not breast-feed